A real-world, triple-cohort study on the effectiveness and safety of telitacicept in immunosuppressant-naïve and refractory lupus nephritis
ObjectiveTo compare the efficacy and safety of telitacicept as add-on therapy versus standard of care (SOC) alone in immunosuppressant (IS)-naïve patients with lupus nephritis (LN) and in patients with refractory LN.MethodsIn this bicentric, real-world…